Taplin ME - Search Results

1

Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).

Francini E, Gray KP, Xie W, Shaw GK, Valença L, Bernard B, Albiges L, Harshman LC, Kantoff PW, Taplin ME, Sweeney CJ. Francini E, et al. Among authors: taplin me. Prostate. 2018 Sep;78(12):889-895. doi: 10.1002/pros.23645. Epub 2018 Apr 29. Prostate. 2018. PMID: 29707790 Free PMC article.

2

High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.

Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin ME, Bubley GJ. Joyce R, et al. Among authors: taplin me. J Urol. 1998 Jan;159(1):149-53. doi: 10.1016/s0022-5347(01)64039-4. J Urol. 1998. PMID: 9400459

3

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ; Cancer and Leukemia Group B Study 9663. Taplin ME, et al. J Clin Oncol. 2003 Jul 15;21(14):2673-8. doi: 10.1200/JCO.2003.11.102. J Clin Oncol. 2003. PMID: 12860943 Clinical Trial.

4

The ingredients for prostate cancer nomograms: the addition of biomarkers sets the table for future recipes.

Taplin ME, Kantoff PW. Taplin ME, et al. J Clin Oncol. 2003 Oct 1;21(19):3552-3. doi: 10.1200/JCO.2003.07.083. Epub 2003 Aug 11. J Clin Oncol. 2003. PMID: 12913104 No abstract available.

5

Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.

Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW. Taplin ME, et al. Urology. 2005 Aug;66(2):386-91. doi: 10.1016/j.urology.2005.03.040. Urology. 2005. PMID: 16098367

6

Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.

Nakabayashi M, Regan MM, Lifsey D, Kantoff PW, Taplin ME, Sartor O, Oh WK. Nakabayashi M, et al. Among authors: taplin me. BJU Int. 2005 Oct;96(6):783-6. doi: 10.1111/j.1464-410X.2005.05714.x. BJU Int. 2005. PMID: 16153200

7

Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study.

Ross RW, Halabi S, Ou SS, Rajeshkumar BR, Woda BA, Vogelzang NJ, Small EJ, Taplin ME, Kantoff PW; Cancer and Leukemia Group B. Ross RW, et al. Among authors: taplin me. Clin Cancer Res. 2005 Nov 15;11(22):8109-13. doi: 10.1158/1078-0432.CCR-05-1250. Clin Cancer Res. 2005. PMID: 16299243

8

Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.

Taplin ME, Xie W, Bubley GJ, Ernstoff MS, Walsh W, Morganstern DE, Regan MM. Taplin ME, et al. J Clin Oncol. 2006 Dec 1;24(34):5408-13. doi: 10.1200/JCO.2006.06.6589. J Clin Oncol. 2006. PMID: 17135641 Clinical Trial.

9

Drug insight: role of the androgen receptor in the development and progression of prostate cancer.

Taplin ME. Taplin ME. Nat Clin Pract Oncol. 2007 Apr;4(4):236-44. doi: 10.1038/ncponc0765. Nat Clin Pract Oncol. 2007. PMID: 17392714 Review.

10

Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.

Pomerantz M, Manola J, Taplin ME, Bubley G, Inman M, Lowell J, Beard C, Kantoff PW, Oh WK. Pomerantz M, et al. Among authors: taplin me. J Urol. 2007 Jun;177(6):2146-50. doi: 10.1016/j.juro.2007.01.119. J Urol. 2007. PMID: 17509304 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

219 results

Search Page